ArticleBMJ public health2024
Integrating SARS-CoV-2 rapid antigen testing in maternal, neonatal and child health, HIV and tuberculosis services in Cameroon and Kenya: a cluster randomised trial of two testing models.
Article in BMJ public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05382130 (INTEGrating Rapid Antigen TEsting for SARS-CoV-2 in Maternal, Neonatal and Child Health, HIV and Tuberculosis Services in Cameroon and Kenya), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
INTEGrating Rapid Antigen TEsting for SARS-CoV-2 in Maternal, Neonatal and Child Health, HIV and Tuberculosis Services in Cameroon and Kenya: A Cluster Randomized Trial of Two Models
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Identifying SARS-CoV-2 infection in high-risk populations is critical. We examined SARS-CoV-2 case detection (CD) in 'TA' versus 'screen-and-test' models of rapid antigen testing integration in maternal neonatal and child health (MNCH), HIV and tuberculosis (TB) clinics in Cameroon (C) and Kenya (K). Methods: From May to October 2022, we conducted a cluster-randomised trial with 10 facilities per country randomised to the 'test-all' (TA) intervention arm or the standard 'screen-and-test' (ST) arm. Individuals aged >2 years attending HIV, TB and MNCH clinics were eligible for SARS-CoV-2 testing. The primary outcome was the SARS-CoV-2 CD, defined as the number of SARS-CoV-2 infections detected per 1 000 attendees in MNCH, HIV and TB clinics. We estimated the intervention arm-specific CDs by combining the facility-specific estimates using a weighted approach. Results: There were 80 828 attendee visits in the TA model (63 492 C, 17 336 K) and 71 254 in the ST model (56 589 C, 14 665 K). About 17.4% (K) and 29.0% (C) were tested under the TA model. The overall CD was 2.90 (95% CI:1.76 to 4.79) per 1 000 attendee visits in the TA model and 1.20 (95% CI:0.73 to 1.99) in the ST model (RR=2.41, 95% CI:1.18 to 4.91, p=0.018). The TA model had a significantly higher SARS-CoV-2 CD in MNCH clinics (2.91 vs 1.11, p=0.012), while CD estimates in HIV (2.88 vs 1.40, p=0.203) and TB (10.24 vs 4.57, p=0.051) clinics, although higher in TA model compared with ST model, were not statistically different. Conclusions: The TA model identified more SARS-CoV-2 cases than the screen-and-test model, even with low testing coverage. The TA model could be considered in future epidemics for early detection of SARS-CoV-2 infection among vulnerable populations, but effective implementation requires additional human resources to manage testing in high volume clinics. Trial registration number: NCT05382130.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.